Regulation of gene activation by the estrogen receptor (ER) is complex and involves co-regulatory proteins, oncoproteins (such as Fos and Jun), and phosphorylation signaling pathways. Here we report the cloning and initial characterization of a novel protein, Brx, that contains a region of identity to the oncogenic Rhoguanine nucleotide exchange (Rho-GEF) protein Lbc, and a unique region capable of binding to nuclear hormone receptors, including the ER. Western and immunohistochemistry studies showed Brx to be expressed in estrogen-responsive reproductive tissues, including breast ductal epithelium. Brx bound speci®cally to the ER via an interaction that required distinct regions of ER and Brx. Furthermore, overexpression of Brx in transfection experiments using an estrogenresponsive reporter revealed that Brx augmented gene activation by the ER in an element-speci®c and liganddependent manner. Moreover, activation of ER by Brx could be speci®cally inhibited by a dominant-negative mutant of Cdc42Hs, but not by dominant negative mutants of RhoA or Rac1. Taken together, these data suggest that Brx represents a novel modular protein that may integrate cytoplasmic signaling pathways involving Rho family GTPases and nuclear hormone receptors.
Introduction
The steroid hormone estrogen determines differentiation of tissues essential for reproduction and is involved in the development of common neoplasms of reproductive tissues, such as breast cancer. Over 40 years of research in many laboratories have led to the understanding that estrogens accomplish ligand-dependent signaling by binding to the estrogen receptor (ER) resulting in association of the receptor with speci®c DNA elements in the promoter regions of hormone responsive genes. Binding of the liganded receptor to DNA results in transcription of speci®c sets of messenger RNAs and alteration of cell function (for review: Tsai and O'Malley, 1994) . The interaction of ligand with receptor results in a conformational change within the receptor which exposes protein interfaces capable of binding transcription factors involved in recruitment of RNA polymerase II and initiation of transcription (Beato and Sanchez-Pacheco, 1996 ; and references therein).
In vivo, however, the mechanism of estrogen action appears to be quite complex, and hormone action may be impacted by other regulatory and signaling pathways within the cell. For example, gene activation by nuclear hormone receptors (NHRs) has recently been shown to include additional proteins that associate directly with receptors, including the estrogen receptor (see : Horwitz et al., 1996; Katzenellenbogen et al., 1996) . Biochemical and interactive cloning methods have led to isolation of 120 (Le Douarin et al., 1995) , 125 (Onate et al., 1995) , 140 (Cavailles et al., 1994 (Cavailles et al., , 1995 Halachmi et al., 1994) , 160 (Halachmi et al., 1994; Cavailles et al., 1994) , 168 (Chen and Evans, 1995) and 270 (Horlein et al., 1995) kDa proteins shown to associate with ligand-bound NHRs and function as positive (co-activators) or negative (corepressors) of nuclear receptor action by modulating interaction with the basal transcription complex. In addition, CBP (and related protein p300) has been described as a`co-integrator' of hormone receptor function through interaction with the nuclear receptor binding protein p160, TFIIB, and Jun/Fos (Kamei et al., 1996) . The identi®cation and characterization of these receptor-binding proteins strongly suggests that ligand-mediated activation of NHRs may be regulated by an additional set of proteins.
Another pathway of NHR activation involves signals emanating from the cell surface that modulate gene activation by nuclear receptors, most probably through receptor phosphorylation (reviewed in: O 'Malley et al., 1995) . Studies have documented eects upon gene activation by nuclear receptors via epidermal growth factor (EGF) (Kato et al., 1995; Bunone et al., 1996; Ignar-Trowbridge et al., 1993) , dopamine (Power et al., 1991; Smith et al., 1993) , TGFa, (IgnarTrowbridge et al., 1993) , insulin-like-growth factor I (IGF-I) (Aronica and Katzenellenbogen, 1993; , cAMP (Aronica and Katzenellenbogen, 1993; Denner et al., 1990) , and heregulin (Pietras et al., 1995) . Data from several laboratories suggest that this second pathway of NHR activation may result in either ligand-independent receptor activation (Bunone et al., 1996; Ignar-Trowbridge et al., 1993) or augmentation of ligand-dependent receptor signaling (Aronica and Katzenellenbogen, 1993; Kato et al., 1995; Ingar-Trowbridge et al., 1993) . For instance, protein kinases such as protein kinase A (PKA) and protein kinase C (PKC) aect ligand-dependent activation of ER; an eect abolished by the addition of the estrogen antagonist, ICI 164384 (Cho and Katzenellenbogen, 1993) . In addition, IGF-1 and agents which increase intracellular cAMP levels, such as cholera toxin/3-isobutyl-1-methylxanthine (CT/ IBMX) and 8-bromo-cyclic-AMP (8-Br-cAMP), caused activation of an ERE-containing reporter equal to that elicited by estradiol alone (Aronica and Katzenellenbogen, 1993) . In vivo studies showed that EGF mimics estrogen regulated functions such as DNA synthesis and augmentation of phosphatidylinositol turnover in the uterus and that both eects were blocked by the addition of the anti-estrogen, ICI 164384 (Ignar-Trowbridge et al., 1992) . Activation of ER by EGF was shown to involve phosphorylation of serine 118 in the amino-terminus of ER through a Ras ± Raf ± mitogen activated protein kinase (MAPK) signaling pathway (Kato et al., 1995; Bunone et al., 1996) . Of interest, nuclear translocation of ER could be induced by EGF; an eect that was inhibited in the presence of a co-transfected dominant negative Ras mutant, rasN17 (Bunone et al., 1996) . In contrast, nuclear translocation induced by estradiol could not be prevented by the overexpression of rasN17, suggesting the existence of at least two independent signaling pathways regulating gene activation by the ER: one involving estrogen, and a second involving small GTPases. Despite compelling data establishing the existence of this cytosolic pathway of receptor activation/modulation, the speci®c steps involved in receptor activation are only partially understood.
Our interest in estrogen receptor function in reproductive tissues led us to investigate proteins in breast tumors that were capable of regulating nuclear receptor function (Segars et al., 1993) . Here we report the cloning and initial characterization of a modular protein, Brx, that belongs to the Dbl oncogene family and contains a nuclear hormone receptor binding region and motifs common to guanine-nucleotideexchange proteins. Brx aected ER-mediated gene activation by a mechanism that was dependent upon Cdc42Hs signaling pathways, but not generalized Rho GTPase activation. These ®ndings suggest that Brx may be involved in`crosstalk' between membrane receptor and nuclear receptor signaling pathways.
Results

Identi®cation and cloning of brx cDNA
Previously, we and others observed that inhibition of estrogen-responsive genes by the retinoid x receptor (RXR) in vitro (Segars et al., 1993) , and possibly estrogen-responsive breast cancer cell growth in vivo (Anzano et al., 1994) , involved an auxiliary protein present in breast cancer cell extracts that interacted with RXR (Segars et al., 1993) , and perhaps ER. The existence of this unidenti®ed auxiliary protein prompted probing of a breast cancer expression library using an interaction cloning strategy for proteins that bound to RXR. Using this approach, we isolated a novel cDNA (Figure 1a ) that not only bound nuclear hormone receptors, but unexpectedly shared structural features with Rho-related signaling proteins (Figure 1b and c) . Since this breast cancer cDNA encoded a nuclear receptor-binding auxiliary protein (Segars et al., 1993) , we called the gene brx. Overlapping cDNA clones were consistent with a 5.3 kilobase cDNA encoding a 1428 amino acid protein with a 168 kilodalton predicted molecular mass distinct from proteins reported to bind nuclear hormone receptors (Cavailles et al., 1994 (Cavailles et al., , 1995 Halachmi et al., 1994; Jacq et al., 1994; Chen and Evans, 1995; Horlein et al., 1995; Onate et al., 1995; Le Douarin et al., 1995; Baniahmad et al., 1995) .
The full length cDNA showed a region of sequence identity to Lbc (Figure 1c) , a partial cDNA associated with acute blast crisis of chronic myelogenous leukemia (Toksoz and Williams, 1994) . Brx therefore belongs to the Dbl superfamily of oncoproteins (Cerione and Zheng, 1996) . We divided the brx cDNA into regions (1 ± 5) based on homology with existing proteins (Figure 1a) . Region (1) was novel and contained an initiator methionine preceded by 4 in-frame stop codons. Region (2) exhibited nucleotide identity to the carboxyl terminus of a partial cDNA (Ht 31), a type II cAMP-dependent protein kinase A-anchoringprotein (Carr et al., 1992) , but lacked a regulatory subunit (RII) binding site (Scott et al., 1990) . Region (3) was novel and contained a diacylglycerol (DAG) binding domain ( Figure 1e ) ± a feature shared by Dbl family members, Vav and Lfc; and signaling proteins Raf kinase, protein kinase C, and n-chimaerin, a Cdc42Hs/Rac GTPase-activating protein (Ahmed et al., 1991) . Region (4) was almost identical to Lbc (identity in 413 of 425 amino acids), suggesting that oncogenic Lbc may represent a truncated form of Brx ( Figure 1c ; and see below). This region is predicted to contain a Dbl homology domain (DH) adjacent to a pleckstrin homology domain (PH) and included the structurally conserved regions (SCR) for Rho GEF proteins SCR1, SCR2, and SCR3 (Boguski and McCormick, 1993) , similar to other Dbl-related proteins (Figure 1d ). These structurally conserved regions did not strictly conform to the PROSITE consensus sequence (Boguski and McCormick, 1993) but were highly conserved between Dbl subfamily members, Lbc, Lfc and Lsc (Figure 1d ). Region (5), consisted of the novel carboxyl terminus of Brx which bound the estrogen receptor (see below) and showed almost no homology to known proteins.
Brx is expressed in reproductive and immune tissues
Northern hybridization revealed that brx mRNAs were expressed in human hematopoietic cells, skeletal muscle, lung and heart as described previously for lbc (Toksoz and Williams, 1994) , but in addition we observed expression in human reproductive tissues (Figure 2a) . A 5.3 kilobase mRNA transcript, a size consistent with the 5.3 kilobase brx cDNA, was detected in breast cancer cell lines, normal breast (not shown) and testis, while larger transcripts were present in the human ovary, placenta and immune tissues. Probing of Northern blots with a labeled fragment from the lbc region of brx (brx nucleotides: 1857-3105) identi®ed the same 5.3 mRNA transcript, consistent with the interpretation that lbc is derived from brx (see Figure 2a) . Similarly, probes prepared from other regions of Brx identi®ed the identical 5.3 kilobase mRNA transcript (not shown). Immunoblot analysis using anity puri®ed antiserum directed against a polypeptide sequence within novel region 5 of Brx detected a *170 kDa endogenously expressed protein in human mammary extracts (Figure 2b ), in agreement with the molecular mass predicted by the amino acid sequence derived from the cDNA. The demonstration of a 170 kDa protein in mammary extracts, which could be speci®cally competed with recombinant Brx protein and/or peptide, supported the conclusion that Brx detected by immunohistochemical studies of mammary cells corresponded to the full-length protein.
Analysis of human tissues using 2665 polyclonal antiserum revealed Brx protein to be expressed in reproductive epithelium. For instance, normal human mammary epithelium, but not stroma, was observed to stain positively for Brx. In particular, we observed that both ER and Brx were highly expressed in the epithelial cells of breast lobules (Figure 3a and b) , Novel regions are shown in black. Scale of 300 base pairs (bp) as indicated. Region 1 contains an initiator methionine preceded by four in-frame stop codons and represents novel sequence. Region 2 is identical to the Ht 31 partial cDNA open reading frame Cterminus at 307 of 310 amino acid residues (amino acid residues 705-1015 of Ht 31) (Carr et al., 1992) . Region 3 contains a diacylglycerol (DAG) consensus binding site. Region 4 is 97% identical at the amino acid level to the Lbc open reading frame and contains a Dbl homology domain (DH) and a consensus EF hand calcium binding domain (EF). Region 5 contains a receptor interaction domain (see below) and sequence identity with two unpublished fragments isolated by EST cloning (yi89b11.r1, base pairs 4630 ± 5134; and HSDHEDC11, base pairs 3053 ± 3881). (b) Predicted amino acid sequence of Brx. The DAG binding site is doubly underlined. DH domain is underlined with a single line and the pleckstrin domain (PH) is boxed. (c) Comparison of domain structure of Brx with sub-family members of Dbl oncogene family, Lbc (Toksoz and Williams, 1994) , Lsc , Lfc (Whitehead et al., 1995) . Schematic diagram of proto-dbl included for comparison (Ron et al., 1988) . Regions of diacylglycerol binding domain (DAG), Dbl homology domain (DH), pleckstrin homology (PH) and EF hand calcium binding domain (EF) regions indicated as shaded areas within bars. Scale of 100 amino acids (AA) is indicated by black bar. (d) Amino acid alignment and comparison of the DH domain of Brx to Dbl and subfamily members, Lbc (Toksoz and Williams, 1994) , Lfc (Whitehead et al., 1995b) , Lsc . Identical amino acids are shaded. Numbers refer to amino acids. Structurally-conserved regions (SCR) conserved in RhoGEF proteins are indicated with a line (see Boguski and McCormick, 1993) . For the DH domain speci®cally, Brx is 99.6% identical to Lbc, 32% for Lsc, 48% for Lfc, and 24% for Dbl. (e) Comparison of diacylglycerol binding site in region 3 of Brx (amino acids 407-453) with other Dbl oncogene family members, Lfc and Vav; and other proteins: protein kinase C (pkc), Unc 13, and a-Raf (Ahmed et al., 1991) . Conserved residues are shaded. Numbers refer to amino acid residues Figure 1a ). An identical pattern of hybridization was observed when a similar mRNA blot was probed with a non-overlapping portion of brx (nt. 1857-3105) corresponding to the lbc region of brx (data not shown) (lower) The same Northern blot probed with b-actin (actin). Molecular weight markers as indicated. (b) Detection of Brx in normal human mammary cell extracts. Anity puri®ed polyclonal antiserum 2665 was generated using a polypeptide sequence derived from region 5 of the predicted open reading frame of Brx (see Materials and methods). Western analysis using 2665 antiserum detected a 170 kDa protein in extracts prepared from normal human mammary tissue (arrowhead, right panel). Lanes: (1) demonstration of speci®c binding of antiserum 2665 to recombinant GST-DN1Brx as a positive control; (2) competition by speci®c peptide #2665; (3) persistence of the band in the presence of competing non-speci®c peptide; (4) detection of a 170 kDa protein in human mammary protein extracts; and (5) competition by peptide (#2665). Consistent with the pattern of expression in Northern analysis, the 170 kDa protein was not present in tissues which did not express brx mRNA (not shown) alternative splicing, and although we have not fully characterized the larger transcripts, the 5.3 kilobase brx transcript encodes a 170 kDa protein which is expressed in reproductive epithelium. Together, the results of Northern, immunoblot, and immunohistochemical studies show Brx expression in ER-containing hormone-responsive cells and tissues, and suggest a role for Brx in modulation of estrogen receptormediated responses in vivo.
Brx interacts with the ER
Next, we used truncated and full-length GST-Brx fusion proteins to test whether Brx bound directly to nuclear hormone receptors. The ER bound most strongly to Brx, but Brx also bound to the RXR, peroxisome proliferator-activated receptor (PPAR), and thyroid hormone receptor ( Figure 4a ). Since binding to ER was avid and Brx was expressed in ER-containing cells, we analysed the requirements for interaction of Brx with ER in vitro (Figure 4b and c).
Truncation of the ER revealed that the ligand-binding domain of ER was required for interaction with Brx.
Deletion of the extreme carboxyl terminus of ER ( Figure 4c , ER[1 ± 551]) did not abolish binding to Brx, suggesting that this region was not required for Brx binding. Conversely, to de®ne the regions of Brx that were required for interaction with ER, coimmunoprecipitation experiments were performed using baculovirus expressed recombinant human ER and truncated, or full-length Brx proteins. These studies revealed both regions 4 and 5 independently were Figure 1a) . Interaction of the Brx fragment with ER is indicated by (+) and (7). Brx (aa: 47-1428, wt Brx); DC1 (aa: 47-396); DN1 (aa: 236-1428); DN2 (aa: 527-1428); DNCa (aa: 527-950); DN3 (aa: 960-1428). (f) Coimmunoprecipitation studies were performed with 35 S-methionine labeled FLAG ± Brx (wt Brx) or labeled Brx derivatives (DC1, DN1, DN2, DNCa, DN3) and resin coated with anti-ER antibody complexed with recombinant baculovirus expressed ER (+), or control resin coated only with anti-ER antibody (7). Input proteins (i). Molecular weight standards as indicated. Luciferase was used as a control (Luc). Estradiol (E2) or ethanol vehicle control (cont) was used at 10 nM. Quantitation showed addition of estradiol to enhance binding of Brx to ER by 1.7-fold. (f) Expression plasmids encoding DN3Brx fused to the VP16 transcription activation domain (Dang et al., 1991 ) (VP16AD-DN3Brx) and/or ER fused to the GAL4 DNA binding domain (Dang et al., 1991) (GAL4-ER) were transfected as indicated into Ishikawa cells together with a GAL4E1b luciferase reporter (present in all lanes). Two experiments were performed in duplicate. Luciferase activity is depicted as fold induction (mean) over control (reporter alone). Expression of transiently transfected fusion proteins (VP16AD-DN3Brx and GAL4-ER) in Ishikawa cells was con®rmed using immunohistochemical detection using antibodies directed against GAL4, the estrogen receptor, and Brx. These studies showed no eect of VP16-AD-DN3 Brx expression upon GAL4-ER expression (or vice versa; data not shown) mRXRβ hER TRα PPARα Luc 
Brx, a novel estrogen receptor binding protein D Rubino et al capable of binding to the ER (Figure 4d and e) . In support of the conclusion that the interaction between Brx and ER was direct, and did not require other bridging proteins, far-Western analysis showed that Brx bound speci®cally to the ER (DMR, unpublished).
To con®rm that Brx and ER could interact in vivo, the interaction was also examined in vivo with a twohybrid transfection system in human endometrial cells. Transfection of a plasmid encoding the ER fused to the GAL4 DNA binding domain showed no activation of a Luciferase-reporter containing ®ve GAL4 binding sites. DN3Brx fused to the VP16 activation domain by itself augmented luciferase activity approximately sixfold. An in vivo interaction between Brx and ER was suggested by a 2.5-fold enhancement of luciferase activity upon transfection of both constructs (Figure 4f ). The magnitude of activation attributable to Brx ± ER interaction in the mammalian dual-hybrid system resembled published levels of activation for two NHR binding proteins; RIP 140 (Cavailles et al., 1995) and CBP/p300 (Sartorelli et al., 1997) . The ability of the VP16DN3Brx construct to cause a slight increase in reporter activity was con®rmed by interaction of Brx protein with other general transcription factors (PHD, unpublished) and will be reported elsewhere. Collectively, the results of both in vivo and in vitro interaction studies suggested that speci®c regions of the ER interacted with Brx.
Brx augments function of the ER
The ability of Brx to aect gene activation by the ER was tested by transient transfection of Ishikawa endometrial cells. Overexpression of Brx (Figure 5a ) markedly augmented reporter activity of an estrogen response element (ERE) containing luciferase reporter plasmid in the presence, but not absence, of estrogen. Furthermore, activation was speci®c for ERE-containing reporter constructs and was not seen with a reporter construct lacking an ERE (Figure 5a , right panel). Control experiments established that dierences in reporter activity could not be attributed to dierences in transfection eciency. Consistent with dependence of the increase in reporter activity upon the ER, addition of the anti-estrogen tamoxifen abolished Brx-dependent activation (Figure 5b ). In the absence of transfected ER, a small ligand-dependent increase in ERE-dependent reporter activity was observed which we attributed to endogenously expressed ER, since all ligand-dependent activation was abolished by addition of 4-hydroxytamoxifen (Figure 5b ). While the increased reporter activity in the presence of RSV ± FLAG ± Brx was ligand-dependent, deletion mutants of Brx were also capable of eliciting a small, but reproducible, ligand-independent activation ( Figure  5a ). The ligand-independent activation by truncated Brx mutants required ER, and was element-speci®c; suggesting that these mutants (perhaps lacking regulatory regions present in full-length Brx) were capable of inducing activation of the ER. Taken together, the transfection studies showed that Brx greatly augmented ER-dependent gene activation in mammalian cells in an element-speci®c and liganddependent manner.
Brx-dependent potentiation of ER activity was attenuated by a Cdc42Hs dominant-negative mutant
We questioned whether activation of ER by Brx might involve Rho-related GTPases, since: (1) Brx contained a Dbl homology (DH) motif; (2) Dbl functioned as a GEF in vitro for Cdc42Hs (Hart et al., 1991) and Rho (Hart et al., 1994) ; and (3) the Lbc oncogene was shown to be a RhoA GEF (Zheng et al., 1995) . We therefore tested dominant negative mutants of three members of the p21 GTPase family, RhoA, Cdc42Hs, and Rac1 (Coso et al., 1995) in cotransfection assays with ER (Figure 5c , left panel) with the hypothesis that Rho-related GTPase activity might be critical for activation of ER by Brx. Brx-dependent potentiation of ER activity was attenuated by a N17Cdc42Hs dominant-negative mutant, in a dose-dependent manner, but not by dominant negative mutants N19RhoA or N17Rac1; indicating that function of Brx may require Cdc42Hs. As a control to con®rm the ability of N17Cdc42Hs to speci®cally repress endogenous Cdc42Hs activity in Ishikawa cells, we examined the eect of the dominant negative mutant on JNK activity, since N17Cdc42Hs was shown to block JNK activity (Coso et al., 1995) . As expected, endogenous activity of JNK (measured by phosphorylation of recombinant Jun) was detected in Ishikawa cells and was augmented by the addition of anisomycin ( Figure  5c , right panel, lane 1), a potent JNK activator. Kinase assays showed that JNK activity was inhibited by cotransfection of N17Cdc42Hs (Figure 5c , right panel, lane 4), thus demonstrating inhibition of endogenous Cdc42Hs activity in our transfection system by the N17Cdc42 expression construct. To con®rm the unexpected observation that Brx-dependent augmentation of the estrogen response did not involve RhoA, we introduced an expression plasmid for clostridium botulinum C3 ADP ribosyltransferase (C3 transferase), since this construct has been shown to inactivate Rho by ADP-ribosylation of Asn-41 (Paterson et al., 1990) . As a control, speci®city of Rho inhibition was con®rmed by transfection of an expression plasmid encoding C3 transferase in Ishikawa cells to show inhibition of RhoAQL activation of a serum response element (SRE) containing reporter plasmid (Figure 5d , right panel), but there was no eect upon activity of Cdc42QL, in agreement with Hill et al. (1993) . In support of our observations suggesting involvement of Cdc42Hs, addition of the expression plasmid for C3 transferase did not (Figure 5d , left panel) attenuate activation of ER by Brx (or DNCa, corresponding to Lbc). While these control experiments supported the proper function of the N17Cdc42Hs construct in Ishikawa cells (Figure 5c ), and the inhibition of RhoA signaling pathways by C3 transferase in Ishikawa cells (Figure 5d) , functionality of the N17Rac mutant (Coso et al., 1995) was not con®rmed by another approach and it is possible that this mutant does not function as expected in Ishikawa cells. In addition, we tested extracts of cells transiently transfected with N17Cdc42Hs to exclude the possibility that expression of either Brx or the estrogen receptor were altered by the N17Cdc42Hs mutant, but these experiments were limited by our inability to detect transiently expressed proteins in our system. With these limitations, the results suggest that Cdc42Hs, but not RhoA, is required for activation of the estrogen responsive reporter by Brx.
Discussion
A century has passed since the demonstration by Beatson that oophorectomy could induce tumor regression in women with metastatic breast cancer (Beatson, 1896) . Estrogen is now universally accepted as a major mitogenic stimulus for endometrial and breast cancers. Due to the prevalence of these neoplasms, a thorough understanding of events involved in activation of the ER is of considerable clinical importance. Consistent with a role for Brx in modulation of ER action, we show that Brx was present in estrogen-responsive epithelium, bound speci®cally to the ER, and augmented ER-dependent reporter activity. In addition, Brx represents a novel Dbl proto-oncogene family member, supporting the conclusion that the function of Brx diers from reported NHR co-activator or co-repressor proteins. This is the ®rst report, to our knowledge, of a protein capable of binding ER and containing a motif involved in guanine nucleotide exchange, though studies have suggested modulation of ER activity by cellular signaling cascades involving small GTPases of the Ras superfamily (see below). In this report we have focused on the role of Brx in reproductive tissues, but given the expression of brx mRNA in other tissues it is quite likely that brx may have a wider physiologic role in cell function. The fact that brx contains a region of identity to lbc (Figure 1 ) suggests that lbc (Toksoz and Williams, 1994 ) is a partial clone of brx and that both transcripts are derived from the same gene. Furthermore, since Lbc is reported to be an exchange factor for RhoA (Zheng et al., 1995) , Brx may be expected to function as a Rho-GEF (see below). Thus, Brx represents a novel member of the Dbl family of oncoproteins (reviewed in: Cerione and Zheng, 1996) which includes: Cdc24 and Bcr (Ron et al., 1991) , Vav (Adams et al., 1992; Galland et al., 1992) , Ect2 (Miki et al., 1993) , Ras GRF (Shou et al., 1992) , Abr (Heisterkamp et al., 1993) , Tim (Chan et al., 1994) , FGD1 (Pasteris et al., 1994) , Lbc (Toksoz and Williams, 1994) , Ost (Horii et al., 1994) , Tiam-1 (Habets et al., 1994) , Dbs (Whitehead et al., 1995a) , Lfc (Whitehead et al., 1995b) and Lsc . The Dbl oncogene was isolated using a transfection focus assay system with DNA from a patient with diuse human B cell lymphoma (Eva and Aaronson, 1985) , and subsequent studies have revealed the dbl oncogene and proto-dbl oncogene (Ron et al., 1988 (Ron et al., , 1991 to regulate cell growth and other diverse cellular functions (Cerione and Zheng, 1996) . Dbl d Figure 5 Augmentation of estrogen receptor-mediated reporter activity by Brx. (a) Expression plasmids encoding ER (+ or 7, as shown), pRSV-FLAG-Brx (Brx), or Brx mutant constructs DN3 (amino acid residues 960 ± 1428), DNCa (residues 527 ± 951) or control (RSV-0), were added to Ishikawa cells with an ERE-tk Luciferase reporter plasmid (left panel), or a tk-Luciferase control reporter (right panel), and harvested after 24 h. Luciferase activity is shown as fold induction (mean) over control (RSV-0 with tkluciferase in the absence of ligand) from three separate experiments, standardized by protein and repeated in triplicate. Estradiol 10 nM (+) or vehicle control (7) was added as shown. Error bars represent standard deviations. Transfection eciency was standardized as described in Materials and methods. (b) Ishikawa cells were transfected with pRSV-FLAG-Brx and ERE-tkluciferase reporter. Expression plasmids for either ER (+), or pKCR2 control plasmid lacking ER (7) were added as shown. Cells were treated with 10 nM estradiol (+E2) or vehicle (7), top line. 1 mM 4-hydroxytamoxifen (OHT) as indicated by (+). Cells were harvested 20 h after addition of ligand. Three independent experiments were performed in triplicate. Values represent % of maximal induction of luciferase activity (mean) over control (ER with pRSV-FLAG-Brx and estradiol). Error bars represent standard deviations. (c) left panel: Brx-dependent activation of ER is inhibited by N17Cdc42Hs. All cells were transfected with pRSV-ER, pRSV-FLAG-Brx and a ERE-tk-luciferase reporter; in addition to decreasing concentrations of expression plasmids for dominant negative mutants pCEV-N17Rac1 (N17Rac1), pCEV-N19RhoA (N19RhoA), and pCEV-N17Cdc42 (N17Cdc42) as denoted by triangles. Dominant negative mutant expression vectors were added to 500, 250, or 0 ng. Concentrations of pCEV were kept constant (at 500 ng) by the addition of pCEV-0. Cells were treated with 10 nM estradiol (+) or vehicle control (7) transferase does not inhibit Brx-dependent activation of ER. All cells were transfected with pRSV-ER and ERE-tk luciferase reporter. 500 ng of pRSV-FLAG-Brx (Brx), pRSV-DNCa (DNCa), or control plasmid (RSV-0) were added in the presence of either 100 ng of pCEV-C3 transferase (C3) or 100 ng of control vector (pCEV-0). Cells were treated with 10 nM estradiol (+) or vehicle control (7) as indicated Luciferase activity from three separate experiments, performed in triplicate, is shown as fold activation over control, pRSV0. Error bars represent standard deviations. Right panel: C3 transferase functions in Ishikawa cells to inhibit activation of the serum response element (SRE) reporter by RhoA, but not by Cdc42Hs. Transfections were performed with constituitively activating mutants, RhoQL (400 ng) and Cdc42QL (400 ng) (Coso et al., 1995) and SRE-luciferase reporter (1 mg) in the presence (+) or 100 ng pCEV-C3 transferase (C3) (Fromm et al., 1997) . pCEV-0 at 100 ng was used as a control (7). Luciferase activity (Reporter Activity) from three separate experiments, performed in duplicate, is shown as per cent dimunition from activation by the constituitively activating mutant(s) family proteins are believed to serve as guanine nucleotide exchange factors for small GTP-binding proteins catalyzing cycling from the`inactive' GDPbound state to the`active' GTP-bound state (see : Symons, 1996) . Dbl was shown to act as a GEF for both Rho and Cdc42Hs in vitro (Hart et al., 1991) ; whereas Lbc showed speci®city for RhoA (Zheng et al., 1995) . Both Dbl and Lbc were shown to induce formation of stress ®bers in vivo (Hart et al., 1994; Zheng et al., 1995) and were capable of inducing anchorage independent growth of 3T3 cells (Schwartz et al., 1996) . Thus, the family of proteins to which Brx belongs are large modular proteins, most of which catalyze guanine nucleotide exchange, and in addition are thought to be coupled to other cellular signaling cascades through distinct regions within the protein.
In some reproductive tissues, a 5.3 kilobase (kb) Brx transcript is observed and antibodies directed against a novel peptide predicted to be present in the Brx protein detected expression of an endogenous protein of 170 kDa (Figure 2b ), consistent with that predicted by the brx cDNA (Figure 1b) . Western analysis using two polyclonal antibodies directed against unique peptide sequences present either in Brx, or Lbc respectively, detected the same 170 kDa band, suggesting that in these reproductive tissues Brx and Lbc epitopes are present on the same polypeptide (unpublished data). In support of these ®ndings, immunohistochemical studies of these tissues with the antiserum directed against Lbc (not shown) gave an identical appearance to experiments performed with the anti-Brx antibodies (Figure 3a and c). These results suggest that in some tissues, Lbc is a domain within a larger Brx protein, and support the conclusion that Lbc is a truncated form of Brx. Lbc cDNAs of 1.8 ± 4.0 kb have been reported, but larger (47.0 kb) mRNA species were noted in mRNA prepared from tissues (Toksoz and Williams, 1994) in agreement with our northern analyses (Figure 2a) , suggesting that rearrangement gave rise to the lbc truncated transcript (Toksoz and Williams, 1994) . However, the expression of an endogenous protein of 47 kDa in mammalian cells, as predicted by the Lbc cDNA, has not been reported. The relationship of Brx to the larger transcripts remains to be clari®ed (here we focus on the 5.3 transcript in reproductive tissues), but in agreement with Toksoz and Williams (1994) , our results indicate that dierent tissues express dierent sized transcripts (Figure 2a) . The lbc cDNA(s) lack amino and carboxyl regions present in the brx cDNA (see Figure 1c ) and we postulate that loss of these regions (which may perform a regulatory role) may contribute to the oncogenic nature of Lbc. For instance, lacking in Lbc are the AKAP and DAG homology regions of Brx, and the novel carboxyl terminus of Brx which contains a region capable of binding to nuclear receptors.
The Dbl subfamily to which Brx belongs is composed of Lbc (Toksoz and Williams, 1994) , Lfc (Whitehead et al., 1995b) , and Lsc . Lfc (Lbc's first cousin) is a 1.8 kb cDNA isolated from murine myeloid cell line, with a 3.7 kb mRNA transcript ubiquitously expressed with the exception of the liver, and contains a DH and PH domain in tandem (Whitehead et al., 1995b) . Lsc (Lbc's second cousin) is a 2.5 kb cDNA isolated from a murine hematopoetic cell line, that contains a DH and PH domain . Lsc mRNA transcripts are found in the thymus, spleen, bone marrow, lung and a breast cancer cell line; but not in the skeletal muscle, heart or brain. Lfc and Lsc, like the prototype Lbc, have been shown to be Rho GEFs in vitro (Glaven et al., 1996) . In agreement with the presence of a Lbc region in Brx, and the tandem arrangement of the DH and PH-domains, our preliminary data show that Brx may function as an exchange factor (GEF) for Rho in vivo (DMR and SG, unpublished data). Unlike Lbc, though similar to Brx (Figure 1c ), Lfc contains a DAG binding domain which may indicate a role in lipid-dependent signaling. In contrast to Vav, the DAG binding domain was not essential for transformation by Lfc in NIH3T3 cells. In addition, Lfc expression in Cos 7 cells has led to activation of JNK (Glaven et al., 1996) , again emphasizing the role of this subfamily in mitogenesis. Lsc, a speci®c Rho GEF in vitro, has demonstrated no guanine nucleotide exchange activity for Cdc42Hs or Rac1, yet dominant negative mutants of Cdc42Hs and Rac1 were able to inhibit focus formation induced by Lsc in NIH3T3 cell lines . These seemingly paradoxical observations suggest that activation of Cdc42Hs/Rac1 pathways may be downstream eectors of Rho GEF activity, or that Lsc has Rho GEF-independent eects on Cdc42/Rac1 signaling pathways. This resembles our ®ndings for Brx which appears capable of functioning as a Rho GEF in vivo (unpublished data), yet its action on estrogen receptor action is speci®cally inhibited by N17Cdc42 (see below). Although prior studies have established a precedent for separate pathways for Cdc42Hs/Rac1 and Rho (Hill et al., 1995; Coso et al., 1995) , further studies will be required to precisely de®ne the putative role of exchange activity in the augmentation of nuclear receptor function by Brx.
Our observation that activation of the ER by Brx was attenuated by a dominant-negative Cdc42Hs mutant suggests a possible role for Brx in the integration of p21GTPase and nuclear receptor signaling pathways. Activation of ER by Brx was not aected by dominant negative mutants of Rac-1, RhoA, or by C3 transferase expression; in agreement with studies documenting distinct signal transduction pathways for these Rho family members (Coso et al., 1995; Minden et al., 1995; Olson et al., 1995) . Rac and Cdc42Hs, originally reported to regulate actin cytoskeletal organization, were more recently shown to interact with proteins involved in mitogenesis and to aect nuclear signaling through activation of transcription by serum response factor (SRF) (Hill et al., 1995) , JNK (Coso et al., 1995; Minden et al., 1995; Olson et al., 1995) , and pp70 S6K (Chou and Blenis, 1996) . The data presented here expand the set of proteins in¯uenced by Cdc42 to include a liganddependent transcription factor, the estrogen receptor. Brx may also integrate GTP signaling with other receptors, since we noted Brx to bind to the thyroid hormone receptor, retinoid X receptor, and peroxisome proliferator-activated receptor (Figure 4a) . Inhibition of estrogen receptor activation by N17Cdc42Hs, coupled with the presence of a DH (GEF) region and a receptor-binding region, suggests that Brx may function as a molecular bridge between transmembrane signaling pathways and nuclear receptor signaling (see below). In keeping with this postulate, Cdc42Hs, has been implicated in seven transmembrane growth factor receptor signaling in both NIH3T3 cells (Nobes and Hall, 1995) and yeast (Zhao et al., 1995) . We note that binding of Brx to ER may not precisely correlate with the ability of Brx to augment estrogendependent reporter activity, since transfection of a Brx expression mutant similar to the DC1 fragment that failed to bind ER (Figure 4d ) did cause a slight increase in estrogen-dependent reporter activity (not shown). This ®nding suggests that activation of the ER by Brx via Cdc42Hs may not be simply equated with binding of Brx to ER, and that other proteins may be involved.
Involvement of small GTP-binding proteins, other than Ras (Kato et al., 1995; Bunone et al., 1996) , in modulation of ER activity has not been previously reported. It has been suggested that activation of a single GTPase by a Rho-GEF (such as Brx) could trigger a cascade of GTPase activation since GTP-binding proteins exist in tightly linked, but independent, regulatory circuits. This raises the possibility that Brx might indirectly aect Rasdependent activation of the estrogen receptor. However, it does not seem that the growth factor Ras ± Raf ± MAPK pathway of ER activation is aected by Brx, since activation of ER by the Ras ± Raf ± MAPK pathway was not inhibited by tamoxifen (Kato et al., 1995) ; whereas, activation of ER by Brx could be abolished by tamoxifen (Figure 5b ). It is possible that cell type, or promoter-speci®c dierences might account for the dierences in response to tamoxifen, since we have not observed activation of an estrogenresponsive promter by tamoxifen in Ishikawa cells, as was observed in COS-1 cells (Kato et al., 1995) . Nevertheless, modulation of estrogen action by small GTP-binding proteins may be of clinical signi®cance, since aberrant Ras signal transduction has been associated with oncogenesis, including some estrogenresponsive breast cancers (Clark and Der, 1995) .
The molecular mechanism of action of Brx is not clear, although Brx is noted to contain phosphorylation sites for MAPK (not shown) in addition to a DAG-binding domain, a signature shared by Vav, Raf, and PKC (Figure 1e ). Furthermore, Brx contains a region of identity to A-kinase anchoring proteins (AKAPs), but lacks the regulatory subunit (RII) binding region characteristic of the AKAP family. Brx does not appear to be a`classic' scaold protein (Faux and Scott, 1996) analogous to Ste5, since Brx contains a region with putative intrinsic enzymatic activity (GEF). Our current working model is that Brx may function in a complex with other proteins to integrate several signaling pathways. This notion is indirectly supported by the observation that molecular chaperone hsp90 (which is known to associate with some nuclear hormone receptors), p50, MEK, and Raf associate as a signaling complex (Wartman and Davis, 1994) . In addition, there is evidence that the 14-3-3 protein (Aitken, 1996 ; and references therein) associates in a higher order complex with Raf and the Brxrelated proteins, Vav and Bcr (Braselmann and McCormick, 1995) . Notably, Brx contains two consensus 14-3-3 binding motifs (aa: 136-142 & 1175-80) near the amino and carboxy terminus of Brx, representing a relationship similar to that found in Raf-1. It is therefore possible that Brx may aect ER function in a complex with hsp90, and other associated proteins. The possibility that Brx may link extracellular and intracellular signaling pathways is in keeping with the function of related Dbl family members that exist in multimolecular complexes and serve as direct links between extracellular signaling cascades, such as integrins (Schwartz et al., 1996) , and nuclear signaling, for instance through JNK (Coso et al., 1995) .
Several experimental observations distinguish Brx from reported co-activator or co-repressor NHRbinding proteins. Notably, Brx did not share sequence homology with reported co-activator proteins. In addition, ligand was not required for in vitro binding of Brx to ER, and in fact the addition of estrogen (Figure 4e ) and tamoxifen (not shown) only slightly augmented binding. A non-ligand dependent interaction has been noted for some NHR-binding proteins (Jacq et al., 1994) , and in some in vitro studies (Cavailles et al., 1995) . Two observations suggest that the mechanism by which Brx functions may involve association with unliganded ER in the cell. First, mammalian dual-hybrid studies supported the conclusion that Brx may bind to the ER in vivo in the absence of ligand. Second, in vitro binding studies including farWestern analysis suggest that ligand is not required for binding of Brx to ER. Precisely how Brx leads to an increase in ligand-dependent function of the ER is not presently understood.
In summary, we have shown that Brx is a novel member of the Dbl superfamily capable of augmenting ligand-dependent estrogen receptor function. We postulate that, in some tissues, Brx may function as an eector protein to integrate estrogen receptor and p21GTPase signaling pathways. Multiple potential phosphorylation sites and the presence of a DAG binding domain suggest a central role for Brx in the convergence of signaling pathways involved in ER activation and the mitogenic eect of ER. The speci®c expression pattern of Brx emphasizes the potential role of Brx in mammary oncogenesis and suggests the importance of further studies designed to elucidate speci®c mechanism(s) by which Brx in¯uences estrogen receptor action.
Materials and methods
Cloning and isolation of brx
Techniques used to probe the ZR75-1 lambda gt-11 expression library by interaction cloning have been described (Arbit et al., manuscript submitted). The original 1.8 kb fragment (2.10) was used as a probe to isolate seven overlapping cDNAs from a lpDR2 testis cDNA library which were subcloned into pBK-RSV (Stratagene) and sequenced. 5'RACE was performed with testis poly(A) + RNA as per manufacturer's instructions (Clontech). Regions of homology were identi®ed using GCG and BLAST programs to search GenBank. Plasmid constructs were made as follows: pDN1 was made by subcloning a 4.05 kb brx cDNA from an independent lambda clone into the BamHI and XbaI sites of pBK-RSV. pDNCa was constructed by ampli®cation of a fragment encoding amino acid residues 534-950 and subcloning into the PstI and XbaI sites of pBK-RSV. pDN2 was generated by digestion of pDN1 with HindIII and XbaI and subcloning a 2483 bp brx cDNA fragment into the HindIII and XbaI sites of pDNCa. A FLAG epitope-tagged Brx expression vector (pRSV-FLAG-Brx) was constructed by digestion of pDN1 with VspI and SalI and subcloning an ampli®ed fragment encoding the 305 N-terminal amino acid residues of Brx fused to a FLAG epitope and an initiator methionine with a consensus Kozak sequence, resulting in a plasmid encoding amino acids 47 ± 1428 of Brx. An expression vector for DC1 Brx was constructed by ampli®cation of brx nucleotides 139 ± 1105, followed by digestion with SalI and BglII and subcloning into SalI and BamHI sites of pBK-RSV. Expression constructs were tested for production of full-length proteins by translation in vitro (TNT, Promega) and were sequenced to con®rm authenticity of ampli®ed segments. The serum response luciferase reporter plasmid (SRE-Luc) was prepared by ampli®cation of the SRE from SRE.L (Hill et al., 1993) and subcloning into pGL2-Basic (Promega).
Northern blot analysis
Northern blots of human tissues (Clontech) and mRNA prepared from ZR-75-1 cells were probed using a a 32 PdCTP-labeled 1.8 kb cDNA fragment (DN3-brx) corresponding to the carboxyl region of brx (nt. 3126 ± 4859), and washed with 0.16SSC at 638C as described (Segars et al., 1993) . Each cDNA clone, including the region of brx corresponding to the lbc oncogene (nt: 1857 ± 3105), was tested by Northern analysis to verify detection of the same transcripts.
Western blot analysis
Rabbit antiserum 2665 was raised against a polypeptide derived from the predicted amino acid sequence (aa: 1091 ± 1121) of Brx. Polyclonal 2665 antiserum anity puri®ed at Covance labs (Vienna, Va.). Proteins from human tissue extracts (Clontech laboratories, San Diego, CA) were resolved in SDS ± PAGE (100 mg/lane), blotted to nitrocellulose and probed with 2665 antiserum essentially as described (Marks et al.,1992) . Immune complexes were detected using enhanced chemiluminescence (Amersham) as per manufactuer's directions. Nonspeci®c peptide-(p34cdc2/cyclin B substrate) was purchased from New England Bio Labs.
Immunohistochemistry
Formalin-®xed breast tissue was deparanized and incubated with anity-puri®ed anti-peptide rabbit-polyclonal antibody for Brx and ER (Novacastra/Vector, Burlingame, CA) overnight at 48C. In other experiments, 12 well plates of cells transiently transfected with expression plasmids were permeabilized with paraformaldehyde, washed, and similarly incubated with respective primary antibody. Tyramide signal ampli®cation peroxidase immunohistochemistry system (TSA-Indirect; DuPont NEN, Boston, MA) or the peroxidase ± biotin ± streptavidin detection kit (Novacastra/Vector Labs) was used as per manufacturer's instructions with diaminobenezidine as a substrate. Competition was performed by incubation of the primary antibody for 2 h at room temperature with puri®ed bacterially expressed recombinant GST-DN1 Brx or GST-0 (control protein). Immuno¯uorescence studies were performed using anti-FLAG M2 antibody 1 : 100 (Eastman Kodak Company) and 1 : 100 dilution of Goat anti-mouse Cy3-conjugated secondary antibody (Jackson Laboratories) on Ishikawa cells transfected with an expression vector, pRSV-FLAGBrx.
GST-binding studies
An EcoRI 1.8 kb DN3 fragment of brx was sub-cloned inframe into the bacterial expression plasmid pGEX2TKB and recombinant GST-DN3Brx and GST-0 control proteins were induced and puri®ed as per manufacturer's instructions (Pharmacia). pEXP-RXRb, pEXP-hT3Rb1, pSG5-mPPARa were generously provided by Drs Susan Nunez, Herb Samuels and Walter Wahli, respectively. 200 000 c.p.m. of 35 S-labeled proteins (TNT, Promega) were incubated with GST-DN3Brx-coated beads for 1 h at 48C in HBB (40 mM HEPES, 75 mM KCl, 0.5 mM EDTA, 5 mM MgCl 2 , 1 mM DTT, 1 mM AEBSF, bovine serum albumin 0.5 mg/ml, and 0.05% nonidet P40). After ®ve wash steps in HBB, bound proteins were eluted in sample buer and analysed by SDS ± PAGE and autoradiography. 10 000 c.p.m. were loaded for each input lane. ER deletion mutants were generated by ampli®cation from HEGO using the following oligonucleotides: ER(1 ± 551) primers (1): 5'-TGAG CGCGCG TAATACG ACTCA CTATAGGG GAATCCA CCACCA TGACCA TGACCC TCCAC ACCA-3', and (2) 5'-CGCATG TAGGCGG TGGGC-3'; ER(1 ± 261): primers (1) above and (3) 5'-CCCTCC TCTTCGG TCTTT-3'; ER(262 ± 595): primers (4): 5'-TGAG CGCGCG TAATACG ACTCAC-TA TAGGGGAA TCCACC ACCATG AGAATG TTGAA ACACA AGCGCCA-3' and (5) 5'-CTCTCA GACTG TGGCAGG-3'. Fragments were then transcribed and translated in vitro (TNT, Promega).
Coimmunoprecipitation studies
Protein A Sepharose resin (Sigma) was washed and blocked in 20 mM Tris HCL, pH 8.0, 5 mM MgCl 2 , 10% glycerol, 1 mM DTT, 1 mM AEBSF, 0.1% IGEPAL (Sigma), 75 mM KCl at 48C for several hours and then incubated with anti-human ER monoclonal Ab (StressGen) and recombinant ER (PanVera) overnight. Immune complexes were washed and incubated for several hours with 200 000 c.p.m. of labeled Brx or control proteins, washed, denatured, and analysed by SDS ± PAGE. DC1 protein was obtained by in vitro translation from VspIlinearized pRSV-FLAG-Brx. Derivation of plasmids for other Brx deletion mutants was described above. Estradiol was added to 10 nM as indicated and vehicle control was EtOH. Each coimmunoprecipitation experiment was performed a minimum of three times.
In vivo interaction studies
Cells were grown in the presence of 1 mM 4-hydroxytamoxifen for 12 h prior to lipofectamine (Gibco-BRL) transfection with 300 ng VP16AD-DN3Brx, 15 ng GAL4-ER, and 1 mg reporter, and were harvested 24 h after transfection. Mammalian two hybrid system plasmids pGAL4 5 E1bCAT, pNL-VP16, and pGAL-0 have been described (Dang et al., 1991) . The GAL4 5 E1b-Luc reporter was constructed by ampli®cation of GAL4 5 E1b promoter sequences from pGAL4 5 E1bCAT and subcloning into pGL2-Basic (Promega). VP16AD-DN3Brx was constructed by ampli®cation of the nuclear localization sequence and VP16 activation domain from pNLVP16. The resulting fragment was fused to the open reading frame from the 1.8 kb DN3Brx cDNA by overlap ampli®cation and subcloned into the mammalian expression vector pBK-RSV. The GAL4 DNA binding domain was ampli®ed from pGAL-0 and the human estrogen receptor open reading frame was ampli®ed from HEGO. The fragments were fused by overlap ampli®cation and subcloned into pBK-RSV. Constructs were tested for expression of full-length proteins by in vitro translation (TNT, Promega) and were partially sequenced. Expression of transfected protein in the dual hybrid system was assessed by immunohistochemistry using anti-FLAG M2, anti-GAL4 DNA binding domain (Santa Cruz) and anti-ER antibodies as described above.
Cell culture and transient transfection
Ishikawa cells were cultured in 12 well plates in DMEM/F-12 with 5% charcoal-stripped fetal bovine serum. 30 ng of pRSV-ER, 0.5 mg of pRSV-FLAG-Brx, 0.5 mg of pRSVDNCa and pRSV0, and 1.0 mg of ERE-tk luciferase (Nunez et al., 1997) were added to cells with Lipofectamine as per manufacturer's directions (Gibco-BRL) where indicated. Cells were harvested after 20 h and luciferase activity was determined as described (Nunez et al., 1997) . Luciferase activities were normalized by protein assay. Transfection eciency was assessed by cotransfection with green uorescent protein expression plasmid (Clontech). Numbers of green cells per ®eld were averaged for 10 ®elds per slide. Over the transfection timecourse, numbers of transfectants were equivalent for each condition. N17Rac1, N17Cdc42Hs, N19RhoA, RhoQL and Cdc42QL were described previously (Coso et al., 1995) . Control expression vector (pCEV-0) was added to give a total of 500 ng of plasmid per well. pCEV-C3 transferase expression plasmid was prepared as described in Fromm et al., 1997 . Ishikawa cells were stably transfected with either a FLAG epitope-tagged Brx expression plasmid, or control plasmid encoding Neomycin resistance (pBK-RSV). Two days later, G418 was added at 800 mg/ml, cells were replated at reduced density, slowly achieved con¯uence, and cell extracts were prepared as described (Segars et al., 1993) .
Jun N-terminal kinase assay
Ishikawa cells were transfected as above; 1 mg of HA-JNK was transfected per 10 cm plate of cells and 25 mg of pCEV-N17Cdc42Hs and pCEV, respectively, were cotransfected. (Note that the scale of transfection is roughly 50-fold greater than for reporter studies). Cells were harvested and JNK assay performed as described (Coso et al., 1995) . Anisomycin 10 mg/ml was added 15 min prior to harvest.
